Liu Shu ming, Sun Yan, Zheng Lei, Zhang Jie, Huang Ming wei, Zhu Jing li, Zhang Zu yan, Zhang Jian guo
Department of Oral and Maxillofacial Surgery, Peking University School, Beijing 100081, China.
Beijing Da Xue Xue Bao Yi Xue Ban. 2011 Feb 18;43(1):102-5.
To evaluate the relative incidence of local control and toxicity in patients with head and neck cancers who underwent external beam radiotherapy (EBRT) plus (125)I seeds implantation.
Ten patients diagnosed as head and neck cancers at the department of oral and maxillofacial surgery of Peking University School of Stomatology during the period of February 2008 to July 2010 were collected. The histologic types included squamous cell carcinoma in 8 patients, poorly differentiated adenocarcinoma of salivary gland in 2 patients. All patients could not receive surgical treatment due to poor medical status or unresectable advanced-stage tumors and underwent EBRT plus (125)I seeds implantation. Eight patients with squamous cell carcinoma had conventional fractionated EBRT with a total dose of 50 Gy; two patients with poorly differentiated adenocarcinoma had conventional fractionated EBRT with a total dose of 70 Gy. They all then had (125)I seeds implantation with matched peripheral dose of 60 Gy (TNM stage I-II) or 80 Gy (TNM stage III-IV ). The apparent activity per seed ranged from 25.9 to 29.6 MBq. follow-up of the patients was done to analyze acute and late toxicity, local control, and survival.
After a median follow-up of 12 months (range 2-28 months), soft tissue necrosis was seen in one patient, dysphagia and hemorrhage in another. No other serious side effects were observed. All the tumor mass of 10 cases disappeared within 6 months, regional metastases was observed in one patient, and distant metastases was observed in another. Seven of 10 patients survived till the date of investigation.
External beam radiotherapy plus (125)I seeds implantation is a safe and effective therapy regimen for patients with unrectable head and neck cancers.
评估接受外照射放疗(EBRT)联合¹²⁵I粒子植入的头颈癌患者局部控制率和毒性反应的相对发生率。
收集2008年2月至2010年7月期间在北京大学口腔医学院口腔颌面外科确诊为头颈癌的10例患者。组织学类型包括8例鳞状细胞癌,2例涎腺低分化腺癌。所有患者因身体状况差或肿瘤晚期无法切除而不能接受手术治疗,均接受了EBRT联合¹²⁵I粒子植入。8例鳞状细胞癌患者接受常规分割EBRT,总剂量为50 Gy;2例涎腺低分化腺癌患者接受常规分割EBRT,总剂量为70 Gy。然后他们均接受¹²⁵I粒子植入,匹配周边剂量为60 Gy(TNM分期I-II)或80 Gy(TNM分期III-IV)。每粒种子的表观活度范围为25.9至29.6 MBq。对患者进行随访以分析急性和晚期毒性反应、局部控制情况和生存率。
中位随访12个月(范围2-28个月)后,1例患者出现软组织坏死,另1例出现吞咽困难和出血。未观察到其他严重副作用。10例患者的所有肿瘤肿块均在6个月内消失,1例患者出现区域转移,另1例出现远处转移。10例患者中有7例存活至调查时。
外照射放疗联合¹²⁵I粒子植入是无法切除的头颈癌患者的一种安全有效的治疗方案。